The National Cancer Institute has announced the launch of a Molecular Analyses for Therapy Choice (MATCH) Clinical Trial, exploring the effectiveness of targeted cancer therapy based on genetic mutation rather than type of cancer. There is a Rare Cancer arm to this trial, so Fibrolamellar patients should be eligible to participate. Please click the link below for details and talk to your doctor to see if this is right for you.
Note: while at this point only adults 18 and over may participate, a pediatric version for those under 18 is in development for early 2016. To keep track of developments in the pediatric version check the following link: http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pediatric-match
Casi Pharmaceuticals is sponsoring a Phase 2 clinical trial which is currently recruiting patients. The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with fibrolamellar. Safety will be measured by looking at the adverse events that may happen and the efficacy will look at the progression of the disease over time. The primary objective of the trial is to determine the 6-month progression free survival (PFS6) rate when patients with advanced fibrolamellar carcinoma (FLC) are treated with daily oral ENMD 2076. A detailed explanation of this trial can be found here. The study chair for this trial is Ghassan Abou Alfa, who is one of FCF's medical and scientifc advisors.
FCF, in collaboration with Johns Hopkins University, will fund a trial involving liver and bone marrow transplants from a patients' relative, for FLC patients where the disease has not spread outside the liver yet but is too advanced to be treated by conventional surgery or transplant. This procedure is intended to remove visible tumor and prevent recurrence by getting the body's immune system to fight the cancer with the new bone marrow. This treatment cannot be used until there is IRB (Institutional Review Board) approval for this combined therapy. Updates about this potential trial will be posted here.
Intellectual property from fibrolamellar discovery dedicated to the public
Intellectual property resulting from the discovery of specific DNA mutations linked to fibrolamellar hepatocellular carcinoma, has been dedicated to the public by the institutions that made the discovery, The Rockefeller University (“Rockefeller”) and the New York Genome Center (“NYGC”). The institutions made this unusual move in the hope of accelerating progress toward the delivery of diagnostics and therapies for this devastating disease. For additional information click the link above.
Major fibrolmellar research published in Science Magazine
A research paper on genetic mutation in fibrolamellar tissue was published February 28, 2014. This research was conducted at the Tucker Davis Research Facility at Rockefeller University. Dr. Sandy Simon is head of the laboratory and his daughter Elana, who is a fibrolamellar patient, was a lead researcher.
Fibrolamellar Tissue Repository opens at the Tucker Davis Research Facility at Rockefeller University.Research on fibrolamellar hepatocellular carcinoma depends on the continued involvement of patients, families and researchers alike. Donations of fibrolamellar tissue are central to the scientific research that will improve the diagnosis, treatment and understanding of this rare disease. The Fibrolamellar Tissue Repository is a tissue bank for fibrolamellar samples obtained during surgery. All patients and families should read this link for details about donating tissue samples.
"FGFR1 and FGFR2 in Fibrolamellar Carcinoma" - http://www.ncbi.nlm.nih.gov/pubmed/26259677
"Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis", http://www.nature.com/modpathol/journal/v18/n11/full/3800449a.html
CONTACT US • JOIN